Apotex Health raises FY2027 revenue growth and EBITDA margin guidance
Apotex Health now guides to 9-10% revenue growth and a 31% adjusted EBITDA margin for FY2027.
Related stories
Brookfield Corporation Reports 16% Increase In Earnings
H impact | EARNINGS | Nov 12, 2026, 12:07 PM UTC
ADI Global Distribution Lowers Full-Year 2026 Outlook
ADI Global Distribution lowered its full-year 2026 outlook, citing Q3 performance and weakness in exclusive brands.
M impact | EARNINGS | Nov 12, 2026, 12:06 PM UTC
Tidewater Midstream Raises FY Adjusted EBITDA Outlook to C$300M–C$320M
M impact | EARNINGS | Nov 12, 2026, 12:04 PM UTC
Legence Raises 2026 Guidance, Authorizes $150M Buyback
Q3 2026 revenue was $1.31B, up 85.1% year over year; excluding Bowers, non-GAAP revenue grew 39.5%. Legence raised its 2026 revenue guidance to $4.87B–$4.91B and adjusted EBITDA gu
M impact | EARNINGS | Nov 12, 2026, 12:02 PM UTC
Forgent Power Solutions Raises FY2027 Revenue Forecast to $2.45B-$2.65B
M impact | EARNINGS | Nov 12, 2026, 12:02 PM UTC
Moderna Raises 2026 Revenue Growth Outlook to 15%–25%
Moderna expects 2026 revenue growth of 15% to 25%, up from its original outlook of up to 10%. It also expects approximately 10 percentage points of gross margin expansion, excludin
M impact | EARNINGS | Nov 12, 2026, 12:02 PM UTC